DocMorris AG: Daniel Wüest becomes new CFO at DocMorris

08.05.24 07:00 Uhr

Werte in diesem Artikel

DocMorris AG / Key word(s): Personnel
DocMorris AG: Daniel Wüest becomes new CFO at DocMorris

08-May-2024 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Frauenfeld, 8 May 2024

Press release
Ad hoc announcement pursuant to Art. 53 LR

Daniel Wüest becomes new CFO at DocMorris

The Board of Directors of DocMorris AG has appointed Daniel Wüest to succeed Marcel Ziwica as CFO. Daniel Wüest will take over his new role on 1 October 2024.

Marcel Ziwica (49) will leave the company at his own request at the end of the year in order to reorient himself professionally after 23 years. Walter Oberhänsli, Chairman of the Board of Directors, commented: “We would like to express our sincere thanks to Marcel Ziwica. With him, a man from the very beginning is leaving the company, who has played a key role in all major projects of the last two decades and who has decidedly shaped the development of DocMorris. The company owes him a lot, both professionally and personally. We wish him all the best for his new start. With Daniel Wüest, DocMorris has been able to gain a competent successor and proven financial expert for this important position.”

The Swiss economist Daniel Wüest (54) has spent the last five years as Group CFO of the listed building supplier Arbonia, where he was actively involved in the strategic and financial realignment of the Group through acquisitions and disposals. Prior to that, Daniel Wüest worked for UBS for more than twenty years in various investment banking positions, where he advised on numerous mergers, acquisitions, debt and equity financings, and IPOs.

CEO Walter Hess is pleased about the new member of the Executive Board: “Daniel Wüest is a proven expert in corporate finance. His broad background of experience in the international corporate environment as well as in financial management and capital markets is extremely valuable to us. I am very much looking forward to working with him. I would like to express my sincere thanks to Marcel Ziwica for his excellent contribution, which is characterised by mutual respect and appreciation, which we will continue until his departure.”

 

Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

20 August 2024 2024 Half-year results (conference call/webcast)
15 October 2024 Q3/2024 Trading update

 

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, marketplace and professional healthcare with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands, with a capacity of over 27 million parcels per year. In Spain and France, the company operates the leading marketplace for health and personal care products in Southern Europe. With its business model, DocMorris offers its patients, customers and partners a broad range of products and services. In doing so, DocMorris is pursuing its vision of creating a digital health ecosystem for everyone to manage their health in one click. The company was renamed from Zur Rose Group AG to DocMorris AG in May 2023 after the Swiss business was sold to Migros/Medbase. Excluding the Swiss business, about 1,600 employees in Germany, the Netherlands, Spain, France and Switzerland generated an external revenue of CHF 1,038 million serving over 9 million active customers in 2023. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

 



End of Inside Information
Language: English
Company: DocMorris AG
Walzmühlestrasse 49
8500 Frauenfeld
Switzerland
ISIN: CH0042615283
Listed: SIX Swiss Exchange
EQS News ID: 1897901

 
End of Announcement EQS News Service

1897901  08-May-2024 CET/CEST

Ausgewählte Hebelprodukte auf DocMorris

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf DocMorris

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Nachrichten zu DocMorris AG (ex Zur Rose)

Analysen zu DocMorris AG (ex Zur Rose)

DatumRatingAnalyst
19.06.2024DocMorris BuyJefferies & Company Inc.
05.06.2024DocMorris BuyJefferies & Company Inc.
04.06.2024DocMorris SellUBS AG
27.05.2024DocMorris BuyWarburg Research
22.05.2024DocMorris AddBaader Bank
DatumRatingAnalyst
19.06.2024DocMorris BuyJefferies & Company Inc.
05.06.2024DocMorris BuyJefferies & Company Inc.
27.05.2024DocMorris BuyWarburg Research
22.05.2024DocMorris AddBaader Bank
23.04.2024DocMorris BuyDeutsche Bank AG
DatumRatingAnalyst
08.01.2024DocMorris Equal-weightMorgan Stanley
31.10.2023DocMorris HoldDeutsche Bank AG
21.10.2023DocMorris HoldDeutsche Bank AG
29.09.2023DocMorris HoldDeutsche Bank AG
29.08.2023DocMorris HoldDeutsche Bank AG
DatumRatingAnalyst
04.06.2024DocMorris SellUBS AG
21.05.2024DocMorris SellUBS AG
16.05.2024DocMorris SellUBS AG
16.04.2024DocMorris SellUBS AG
02.04.2024DocMorris SellUBS AG

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für DocMorris AG (ex Zur Rose) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"